


Supplementary Material

Supplementary Figure 1. Percentage of patients with enthesitis (a) overall analysis; (b) remainder analysis or dactylitis; (c) overall analysis; (d) remainder analysis



Data shown as percentage of patients with enthesitis or dactylitis at baseline, 12 months, and 36 months (LOCF).

Error bars represent 95% CI.

The overall analysis included patients switching/stopping their original treatment during the 3-year observation period. The remainder analysis reflects 3-year data from assessments for patients still under initial treatment at 3 years.

BL, baseline; CI, confidence intervals; TNFi, tumour necrosis factor inhibitors; UST, ustekinumab

Supplementary Table 1. Mean swollen joint counts at baseline, 1 year and 3 years for overall patients (n=895) and remainers (n=437) (LOCF analysis)

| Mean (SD)[95%CI] | UST overall (n=439) | TNFi overall (n=456) | UST remainers (n=219) | TNFi remainers (n=218) |
|---|--|--|--|--|
| Swollen joint count at baseline | n=439 5.8 (8.1) [5.0; 6.6] | n=456 5.9 (7.6) [5.2; 6.7] | n=219 6.1 (8.5) [4.9; 7.2] | n=218 7.0 (8.7) [5.8; 8.3] |
| Swollen joint count at 1 year Change from baseline at 1 year | n=298 1.8 (3.8) [1.3; 2.2] -4.4 (7.9) [-5.5; -3.5] | n=293 1.2 (2.4) [0.9; 1.5] -4.7 (6.9) [-5.5; -3.9] | n=190 1.5 (3.5) [1.0; 2.0] -4.7 (8.3) [-5.9; -3.5] | n=185 0.9 (1.9) [0.7; 1.2] -5.7 (7.8) [-6.9; -4.6] |
| Swollen joint count at 3 years Change from baseline at 3 years | n=384 2.0 (4.8) [1.5; 2.4] -3.9 (7.9) [-4.7; -3.1] | n=373 1.5 (4.2) [1.1; 2.0] -4.4 (7.6) [-5.2; -3.6] | n=204 0.7 (2.4) [0.3; 1.0] -5.4 (8.2) [-6.5; -4.3] | n=196 0.9 (4.0) [0.3; 1.5] -6.2 (9.0) [-7.4; -4.9] |

The overall analysis included patients switching/stopping their original treatment during the 3-year observation period. The remainder analysis reflects 3-year data from assessments for patients still under initial treatment at 3 years.

CI, confidence interval; LOCF, last observation carried forward; SD, standard deviation; TNFi, tumour necrosis factor inhibitors; UST, ustekinumab